Article info
PDFEditors’ commentary
Highlights from this issue
Citation
Highlights from this issue
Publication history
- Accepted June 22, 2020
- First published July 19, 2020.
Online issue publication
July 31, 2020
Article Versions
- Previous version (31 July 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
- Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment
- Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
- Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity
- Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization
- Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models
- Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
- Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia
- PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages
- Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells